title: Managing Treatment-Resistant Patients.
abstract: Treatment-resistant hypertension (TRH) has a prevalence of approximately 10-20 %, and up to 5 % of patients with TRH experience a major cardiovascular or cerebrovascular event each year. Effective management of real TRH is important but can present a significant clinical challenge. Utilisation of treatment options that maximise treatment compliance is recommended, particularly combinations that have supporting data from clinical studies. Renal denervation can be considered for a subset of truly resistant patients.
authors.affiliation: Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, Roland.Schmieder@uk-erlangen.de.
authors.forename: Roland E
authors.initials: RE
authors.lastname: Schmieder
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D007668:Kidney / Q000294:innervation*; D013562:Sympathectomy; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents